Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base

Olszewski Adam J.; Winer Eric S.; Castillo Jorge J.

首页> 外文期刊>Cancer causes and control: CCC >Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base

【24h】

Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base

机译：在国家癌症数据库中验证弥漫性大B细胞淋巴瘤的临床预后指标

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Accurate risk stratification is necessary for epidemiologic and outcomes research in diffuse large B-cell lymphoma (DLBCL). We evaluated performance characteristics of the clinically derived International Prognostic Index (IPI) and revised IPI (R-IPI) with a regression model-based score using the National Cancer Data Base.

机译：对于弥散性大B细胞淋巴瘤（DLBCL）的流行病学和结局研究，准确的风险分层是必要的。我们使用国家癌症数据库，通过基于回归模型的评分，评估了临床衍生的国际预后指数（IPI）和修订的IPI（R-IPI）的表现特征。

著录项

来源
《Cancer causes and control: CCC》 |2015年第8期|共10页
作者
Olszewski Adam J.; Winer Eric S.; Castillo Jorge J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Diffuse large B-cell lymphoma; Non-Hodgkin lymphoma; Prognosis; Epidemiology; Outcomes research; Survival analysis; Model validation;

机译：弥漫性大B细胞淋巴瘤;非霍奇金淋巴瘤;预后;流行病学;结果研究;生存分析;模型验证;

相似文献

外文文献
中文文献
专利

1. 采用美国国家癌症数据库数据分析淋巴浸润性微乳头状乳腺癌的预后 [J] . Gary D.Lewis, Jenny Chang, Bin S.Teh, 癌症（英文版） . 2020,第002期
2. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base [J] . Olszewski Adam J., Winer Eric S., Castillo Jorge J. Cancer causes and control: CCC . 2015,第8期

机译：在国家癌症数据库中验证弥漫性大B细胞淋巴瘤的临床预后指标
3. A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry [J] . Gang Anne O., Pedersen Michael, dAmore Francesco, Leukemia and lymphoma . 2015,第9期

机译：弥漫性大B细胞淋巴瘤的临床预后指标，在70岁时就可以有效地改善预后分层：丹麦淋巴瘤注册中心基于人群的分析
4. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG) (see comments) [J] . Cortelazzo S, Rossi A, Roggero F, Annals of oncology: official journal of the European Society for Medical Oncology . 1999,第12期

机译：经阶段修改的国际预后指数可有效预测局部原发性胃弥漫性大B细胞淋巴瘤的临床预后。国际淋巴结外淋巴瘤研究小组（IELSG）（见评论）
5. Mutational profile of Diffuse Large B-cell Lymphoma with central nervous system relapse: analysis of CBioPortal for Cancer Genomics database [C] . Elena Voropaeva, Olga Beresina, Tatyana Pospelova, Conference on Cognitive Sciences, Genomics and Bioinformatics . 2020

机译：弥漫性大B细胞淋巴瘤与中枢神经系统复发的突变特征：用于癌症基因组学数据库的CBioPortal分析
6. A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B-cell lymphoma in the rituximab era [D] . Ishikawa Eri, 石川恵里 2019

机译：利妥昔单抗时代的原发性胃弥漫性大B细胞淋巴瘤的预后模型，包括肿瘤细胞的EBV状态
7. Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study [O] . HONG-HUI HUANG, FEI XIAO, FANG-YUAN CHEN, -1

机译：对弥散性大B细胞淋巴瘤患者的国际预后指数和修订后的国际预后指数的预后价值的重新评估：一项多中心研究
8. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-Cell Non-Hodgkin’s lymphoma1,2 1Expert panel members and authors of the review are: Theresa Hahn, PhD, Roswell Park Cancer Institute, Buffalo, NY; Steven N. Wolff, MD, Vanderbilt University, Nashville, TN, Myron Czuczman, MD, Roswell Park Cancer Institute, Buffalo, NY; Richard I. Fisher, MD, Cardinal Bernardin Cancer Center, Loyola University, Chicago, IL; Hillard M. Lazarus, MD, Comprehensive Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH; Philip L. McCarthy, MD, Roswell Park Cancer Institute, Buffalo, NY; Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE; Lisa Warren, Cure for Lymphoma Foundation, New York, NY; and Richard Watt, MD, United Resource Networks, Minneapolis, MN. 2Reference: Hahn T, Wolff SN, Czuczman M, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin’s lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2001;7:308–331. [O] . 2003

机译：造血干细胞移植的细胞毒性治疗在治疗弥漫性大细胞B细胞非霍奇金淋巴瘤1,2中的作用1，专家小组成员和评价的作者是：纽约州布法罗罗斯威尔公园癌症研究所的特蕾莎·哈恩博士；田纳西州纳什维尔范德比尔特大学医学博士斯蒂芬·沃尔夫（Steven N. Wolff），纽约州布法罗罗斯维尔公园癌症研究所医学博士迈伦·库兹曼（Myron Czuczman）；理查德·费舍尔（Richard I. Fisher）医学博士，伊利诺伊州芝加哥洛约拉大学贝纳尔丁枢机主教癌症中心；俄亥俄州克利夫兰凯斯西储大学克利夫兰大学医院综合癌症中心医学博士Hillard M. Lazarus；纽约州布法罗罗斯韦尔公园癌症研究所医学博士Philip L.内布拉斯加州奥马哈市内布拉斯加大学医学中心医学博士Julie Vose；丽莎·沃伦（Lisa Warren），纽约州纽约市淋巴瘤基金会的治疗；和明尼苏达州明尼阿波利斯市联合资源网络公司的医学博士Richard Watt。 2参考文献：Hahn T，Wolff SN，Czuczman M等。一项基于证据的综述：造血干细胞移植的细胞毒性治疗在弥漫性大细胞B细胞非霍奇金淋巴瘤治疗中的作用。 Biol骨髓移植。 2001; 7：308-331。

Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base

摘要

著录项

相似文献

相关主题

期刊订阅